An In-Depth Overview of Interstitial Lung Diseases for Healthcare Professionals
OthersPage Navigation
Introduction
Interstitial lung diseases (ILDs) represent a heterogeneous group of more than 200 conditions characterized by inflammation and fibrosis of the lung interstitium, leading to progressive dyspnea and cough.
Etiology and Classification
ILDs can be idiopathic, related to systemic diseases, or due to environmental exposures. The most common idiopathic ILD is idiopathic pulmonary fibrosis (IPF). Other forms include nonspecific interstitial pneumonia and sarcoidosis.
Clinical Manifestations and Diagnosis
Patients typically present with progressive dyspnea and dry cough. Physical examination may reveal crackles and clubbing. High-resolution CT is the gold standard for diagnosis. Pulmonary function tests show a restrictive pattern and reduced diffusion capacity.
Treatment and Prognosis
Treatment is largely supportive, including oxygen therapy and pulmonary rehabilitation. Antifibrotic drugs like pirfenidone and nintedanib are approved for IPF. Prognosis varies widely, with IPF having a median survival of 2-3 years post-diagnosis.
Conclusion
ILDs are complex disorders requiring a thorough understanding for effective management. Further research is needed to develop more effective treatments and improve patient outcomes.
Recommended News For You
Recommended Articles For You
Featured News
Featured Articles
Featured Events
Featured KOL Videos
1.
Increasing Access to Prostate Cancer Drugs; Reducing Toxic Emissions; FTC Files a 'Charity' Suit.
2.
Compared to previous estimates, a greater number of patients participate in cancer treatment trials.
3.
Higher levels of HIF2α found to slow down aggressive childhood cancer
4.
PPI, Antibiotics May Curb Durvalumab Efficacy in NSCLC
5.
Increased detection of adenomas may reduce colon cancer risk after colonoscopy in FIT-based screening.
1.
Screening for Functional Vulnerability in Long-Term Cancer Survivorship
2.
Revolutionizing Lung Transplantation: The Promise of Donor-Specific Blood Transfusion
3.
Toxicity Surveillance for Bispecific Cancer Therapies
4.
Childhood Cancer Survivorship and Tissue Aging: Clinical Insights and Mechanistic Perspectives
5.
Practical Breakthroughs in Oncology Across Clinical Settings
1.
International Conference on Oncology, Cancer Prevention and Public Health
2.
International Conference on Cancer Nursing and Rehabilitation Strategies
3.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
4.
International Conference on Innovations in Critical Care for Oncology and Cardiology
5.
International Symposium on Oncology, Cardiology and Critical Care Innovations
1.
A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC
2.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma
3.
Efficient Management of First line ALK-rearranged NSCLC - Part IV
4.
Navigating the Complexities of Ph Negative ALL - Part XIV
5.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Welcome to Hidoc Dr.
Join to enhance your clinical skills and gain specialized in-depth medical knowledge